VAC 3S

Drug Profile

VAC 3S

Alternative Names: VAC-3S

Latest Information Update: 18 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Assistance Publique Hopitaux de Paris; INSERM; Universite Pierre et Marie Curie
  • Developer InnaVirVax
  • Class AIDS vaccines
  • Mechanism of Action HIV envelope protein gp41 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 18 Oct 2018 VAC 3S is still in phase IIa trials for for HIV infections (InnaVirVax website, October 2018)
  • 24 Jun 2018 Biomarkers information updated
  • 04 Mar 2018 Efficacy and adverse events data from a phase II trial in HIV-1 infections presented at the 25th Conference on Retroviruses and Opportunistic Infections (CROI-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top